Sagel Scott D
Departmentof Pediatrics, Children's Hospital, University of Colorado Health Sciences Center, Denver, 80218, USA.
Curr Opin Pulm Med. 2003 Nov;9(6):516-21. doi: 10.1097/00063198-200311000-00012.
Airway inflammation plays a central role in the lung disease of cystic fibrosis (CF). Biomarkers of inflammation may be useful for monitoring disease progression and evaluating response to therapy. Much of our knowledge of the chronic inflammatory process in the CF airway derives from studies of bronchoscopy and bronchoalveolar lavage. A number of noninvasive approaches have been recently developed to more readily assess airway inflammation including sputum induction, collection of exhaled air, analysis of systemic markers of inflammation, and computed tomography imaging.
While measurements of biomarkers of inflammation continue to advance our understanding of the underlying disease process, there is as yet no established role for these markers in clinical practice. This review summarizes the current state of knowledge of various inflammatory markers relevant to CF lung disease, with an eye towards application as surrogate outcome measures in CF clinical trials.
It is hoped that biomarkers obtained by noninvasive means will be useful in determining specific pathways of injury (ie, oxidative or proteolytic) in individual persons with CF and in assessing response to antiinflammatory treatments.
气道炎症在囊性纤维化（CF）肺部疾病中起核心作用。炎症生物标志物可能有助于监测疾病进展并评估治疗反应。我们对CF气道慢性炎症过程的许多了解都来自支气管镜检查和支气管肺泡灌洗研究。最近已开发出多种非侵入性方法来更轻松地评估气道炎症，包括痰液诱导、呼出气收集、炎症系统标志物分析和计算机断层扫描成像。
虽然炎症生物标志物的测量继续增进我们对潜在疾病过程的理解，但这些标志物在临床实践中尚未确立明确作用。本综述总结了与CF肺部疾病相关的各种炎症标志物的当前知识状态，着眼于在CF临床试验中作为替代结局指标的应用。
希望通过非侵入性手段获得的生物标志物将有助于确定个体CF患者的特定损伤途径（即氧化或蛋白水解），并评估对抗炎治疗的反应。
